Cerus Corporation is a biomedical products company focused on the field of blood safety
The INTERCEPT™ Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. Cerus currently markets and sells the INTERCEPT™ Blood System for both platelets and plasma in the United States, Canada, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT™ red blood cell system is in clinical development.
JOIN THE MOVEMENT.
Nearly 2.5 million platelet units are treated with the INTERCEPT™ Blood System each year.
Providing proven broad pathogen inactivation (PI) efficacy backed with extensive clinical evidence, INTERCEPT™ Blood System is the preferred choice in >300 Blood Centres and >40 Countries.
I saw the devastation that bacterial contamination could cause. It was something that I wanted to make sure would never happen again. When I learned that INTERCEPT™ Platelets were available, it was a no-brainer to me to say, okay, we need to adopt this technology.
Mary Berg, MD
Medical Director, Transfusion Medicine Service, University of Colorado
You may also be interested in
There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19, and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT™ process. For a full list of warnings, precautions for use and pathogens inactivated, please refer to the Technical Data Sheet and Instructions for Use found in the resource section of this website.